Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

B-Raf Signaling

  • Tilman Brummer
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_704-4

Synonyms

Definition

B-Raf signaling comprises the activation of the proto-oncogene product B-Raf and its downstream effectors and represents a key regulatory step in the activation of the canonical MAP kinase pathway by various extracellular stimuli and oncogene products such as Ras and activated receptor tyrosine kinases (RTKs) like NTRK and RET. Aberrant B-Raf activity as a result of somatic mutations is observed in 8 % of human cancers.

Characteristics

Physiological Aspects of B-Raf Signaling

B-Raf is a member of the Raf kinasefamily and represents an important component of the Ras/Raf/MEK/ERK MAP kinase signal transduction pathway, which plays a pivotal role in growth control and differentiation. Dysregulation of this pathway is observed in about 30 % of human tumors and represents an established mechanism for tumorigenesis. In their role as gatekeepers of...

Keywords

Papillary Thyroid Carcinoma Hairy Cell Leukemia BRAF Gene Oncogene Addiction Murine Sarcoma Viral Oncogene Homolog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Cseh B, Doma E, Baccarini M (2014) “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett 588:2398–2406PubMedPubMedCentralCrossRefGoogle Scholar
  2. Lavoie H, Therrien M (2015) Regulation of RAF protein kinases in ERK signalling. Nature reviews. Mol Cell Biol 16:281–298Google Scholar
  3. Röring M, Brummer T (2012) Aberrant B-raf signaling in human cancer – 10 years from bench to bedside. Crit Rev Oncog 17:97–121PubMedCrossRefGoogle Scholar
  4. Samatar AA, Poulikakos PI (2014) Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 13:928–942PubMedCrossRefGoogle Scholar
  5. Wu CJ (2014) Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. J Clin Investig 124:4681–4683PubMedPubMedCentralCrossRefGoogle Scholar

See also

  1. (2012) Activation loop. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 23. doi:10.1007/978-3-642-16483-5_50Google Scholar
  2. (2012) AKT. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 115. doi:10.1007/978-3-642-16483-5_163Google Scholar
  3. (2012) Angiogenic switch. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 186. doi:10.1007/978-3-642-16483-5_277Google Scholar
  4. (2012) DT40. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1168. doi:10.1007/978-3-642-16483-5_1747Google Scholar
  5. (2012) Geldanamycin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 1516-1517. doi:10.1007/978-3-642-16483-5_2357Google Scholar
  6. (2012) Immediate early genes. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1811. doi:10.1007/978-3-642-16483-5_2967Google Scholar
  7. (2012) In vitro kinase assay. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1839. doi:10.1007/978-3-642-16483-5_3218Google Scholar
  8. (2012) Neuro-Cardio-Facial-Cutaneous Syndromes. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2480. doi:10.1007/978-3-642-16483-5_4024Google Scholar
  9. (2012) P53. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2747. doi:10.1007/978-3-642-16483-5_4331Google Scholar
  10. (2012) Senescence. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3370. doi:10.1007/978-3-642-16483-5_5236Google Scholar
  11. (2012) Signalosome. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3411. doi:10.1007/978-3-642-16483-5_5305Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Institute of Molecular Medicine and Cell ResearchAlbert-Ludwigs-UniversityFreiburgGermany